The asthma spacers market is expected to reach a market size worth US$2,255.289 million by 2026, growing at a CAGR of 4.45%. This market was valued at US$1,662.812 million in 2019. An asthma spacer is a holding chamber that is attached to an asthma medicine dispensing machine, commonly known as an inhaler, that facilitates slower and effective inhalation of the medicine. An asthma inhaler converts the medicine in gas form and delivers it to the patients’ lungs, opening the airways. However, the inhaler has less mouth space and rushes the medicine in the person's airways, making the hard to inhale the medicine and even leading to wastage. A spacer is attached to the inhaler, which is a long tube, that enables the patients to slowly inhale the medicine reducing the wastage and enabling better inhalation. Increasing cases of asthma owing to the rise in pollution and growing cases of chronic diseases are expected to drive the market growth during the forecasted period. Rising cases of asthma, especially among children, are expected to drive the market demand since children find it difficult to directly inhale through the inhaler.
Geographically, the asthma spacer market is divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific regions for the study. The Asia Pacific asthma spacer market is expected to grow at a lucrative rate during the forecasted period. Surging air pollution to hazardous levels has significantly increased the cases of asthma among all age groups, children being the worst affected. Data from UNEP shows that 70% of air pollution-linked deaths occur in the Asia Pacific region. Asthma is the prime chronic disease that prevails due to air pollution and causes death. Growing cases of asthma are expected to drive the market demand for asthma spacer in the region North America and European regions are anticipated to dominate the market owing to higher expenditure capability and significant users.
Asthma is a widely prevailing respiratory chronic disease that affects the airways, making it difficult for the person to breathe owing to narrowed and/ or swelled up airways. One of the prime reasons which are expected to drive the market growth of asthma spacer is growing cases of asthma around the world, and especially among children. Data from the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) shows that globally, more than 3 billion people suffer from asthma. World Health Organization database shows that 461,000 people died because of this disease in the year 2019. Increasing cases of asthma owing to family genetics and rising air pollution are expected to increase the adoption of asthma inhalers and spacers hence driving the market growth during the forecast period.
The World Health Organization (WHO) aims to reduce global asthma under its Global Action Plan for the Prevention and Control of NCDs, 2030. A study by the organization observed that only 1/5th of patients suffering from asthma have access to inhalers and the majority were not aware of the usage and importance of spacers. In its guidelines and awareness programs, WHO promoted the making and usage of homemade spacers using plastic bottles which could be substituted for branded asthma spacers. The low cost of the homemade spacers accompanied by high treatment and medication costs encourages the adoption of DIY spacers, especially in low-income countries, and hence constraints the prospective opportunity for the market.
Furthermore, the development of technology and the launch of new products that do not require a spacer for inhalation pose a significant market threat for asthma spacers. Teva Pharmaceuticals. for instance, has successfully formulated spacer-free asthma medication which enables better breathing by the patients. QVAR® RediHaler™ is an FDA-approved spacer-free technology that delivers medication as effectively as its predecessor. QVAR® RediHaler™ has been developed around breath-actuated inhaler technology and is apt for 4 years and older patients, which can be used without the spacer even for children. The rise in such technology is expected to hinder the market for the asthma spacer industry.
With the outbreak of the virus, governments around the world implemented a nationwide lockdown which confined the population within the four walls of their homes. The covid-19 virus is a respiratory system affecting virus which makes breathing hard for the affected person. Furthermore, the virus was observed to cause a more serious impact on patients already suffering from chronic diseases, especially asthma, and other respiratory diseases. With the outbreak of the virus and growing cases, people adopted inhalers and spacers for greater medicine delivery, supporting the market.
|Market size value in 2019||US$1,662.812 million|
|Market size value in 2026||US$2,255.289 million|
|Growth Rate||CAGR of 4.45% from 2019 to 2026|
|Forecast Unit (Value)||USD Million|
|Segments covered||Product Type, Distribution Channel, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Zydus Cadila, Pari Gmbh, Cipla, Glaxo SmithKline Pharmaceuticals Ltd, Rossmax International Ltd., Lupin|
|Customization scope||Free report customization with purchase|
Key Market Segments
Frequently Asked Questions (FAQs)
Q1. What will be the asthma spacers market size by 2026?
A1. The asthma spacers market is expected to reach a total market size of US$2,255.289 million in 2026.
Q2. What are the growth prospects for the asthma spacers market?
A2. The global asthma spacers market is expected to grow at a CAGR of 4.45% over the forecast period.
Q3. What is the size of the global asthma spacers market?
A3. Asthma Spacers Market was valued at US$1,662.812 million in 2019.
Q4. Which region holds the largest market share in the asthma spacers market?
A4. North America and European regions are anticipated to hold a significant share of the asthma spacers market.
Q5. What factors are anticipated to drive the asthma spacers market growth?
A5. Increasing cases of asthma owing to the rise in pollution and growing cases of chronic diseases are expected to drive the asthma spacers market growth.
Glaxo SmithKline Pharmaceuticals Ltd
Rossmax International Ltd.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.